Research Associate Professor
Department of Pharmacological and Pharmaceutical Sciences
University of Houston College of Pharmacy
Health 2, Room 7040
4349 Martin Luther King Boulevard
Houston, TX 77204-5037
Contact: firstname.lastname@example.org - 713-743-7349 - Fax: 713-743-1884
Cancer Research, Biochemistry, Molecular Biology, Animal Physiology and Pharmacology, Pharmaceutical Sciences, Cancer chemotherapy, Antisense therapy and gene silencing, Regulation of oncogene and tumor suppressor gene, Disease model, Preclinical and clinical drug development, Translational research/clinical trials
- Ph.D. (Molecular Pharmacology), Fudan University, School of Pharmacy, China
- B.M. (MD equivalent) with Honor, Changzhi Medical College, China
Google Scholar Profile
- Punganuru SR, Artula V, Zhao W, Rajaei M, Deokar H, Zhang R, Buolamwini JK, Srivenugopal KS, Wang W. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 2020 Jul 1;9(7).
- Wang W, Qin JJ, Rajaei M, Li X, Yu X, Hunt C, Zhang R. Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev. 2020;40(3):856-880.
- Wang W, Wang X, Rajaei M, Youn JY, Zafar A, Deokar H, Buolamwini JK, Yang J, Foster JH, Zhou J, Zhang R. Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action. Cancers (Basel). 2020;12(12).
- Wang W, Cheng JW, Qin JJ, Hu B, Li X, Nijampatnam B, Velu SE, Fan J, Yang XR, Zhang R. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett. 2019;459:156-167.
- Wang W, Hu B, Qin JJ, Cheng JW, Li X, Rajaei M, Fan J, Yang XR, Zhang R. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis. 2019 Dec;6(4):419-430.
- Wang W, Qin JJ, Voruganti S, Nijampatnam B, Velu SE, Ruan KH, Hu M, Zhou J, Zhang R. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res. 2018;78(19):5656-5667.
- Wang W, Qin JJ, Li X, Tao G, Wang Q, Wu X, Zhou J, Zi X, Zhang R. Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis. 2018;39(8):1026-1036.
- Wang W, Qin JJ, Voruganti S, Nag S, Zhou J, Zhang R. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev. 2015;35(6):1220-67.
- Wang W, Nag S, Zhang X, Wang MH, Wang H, Zhou J, Zhang R. Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications. Med Res Rev. 2015;35(2):225-85.
- Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice. Gastroenterology. 2014;147(4):893-902.e2.
- Wang W, Qin JJ, Voruganti S, Srivenugopal KS, Nag S, Patil S, Sharma H, Wang MH, Wang H, Buolamwini JK, Zhang R. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nat Commun. 2014;5:5086.
- Wang W, Rayburn ER, Zhao Y, Wang H, Zhang R. Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett. 2009;278(2):241-248.
- Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugesan S, Zhang R. In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res. 2009;15(10):3511-8.
- Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer. 2008;98(4):792-802.
- Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol. 2007;59(5):589-601.